Lates News

date
03/07/2025
Lilly announced that Mu Fengda (tesamorelin injection) has been approved by the China National Medical Products Administration (NMPA) to become the first and currently only prescription drug for the treatment of obstructive sleep apnea (OSA) in adults with moderate to severe obesity. Tesamorelin can improve sleep disorders in obese adults with moderate to severe obstructive sleep apnea. The use of this indication should be based on controlling diet and increasing exercise. (21st Century Business Herald)